Literature DB >> 1202895

L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.

P Bergonzi, C Chiurulla, D Gambi, G Mennuni, F Pinto.   

Abstract

Sixty-four all-night sleep polygraphic recordings have been carried out in patients affected by Parkinson's syndrome, before and after treatment with an association of l-dopa plus a peripheral dopa-decarboxylase inhibitor. Without any drug, parkinsonian patients showed sleep disruption with frequent awakenings, reduction of total sleeping time and lessening of REM stage rather than slow sleep. Treatment with l-dopa plus inhibitor appeared to be able to restore good night sleep organization with a noteworthy increase in the REM stage.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1202895

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  10 in total

Review 1.  Drug-induced sleep disturbances. Focus on nonpsychotropic medications.

Authors:  M Novak; C M Shapiro
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

2.  Reduced rapid eye movement sleep latency in patients with Parkinson's disease.

Authors:  V S Kostić; V Susić; N Covicković-Sternić; Z Marinković; S Janković
Journal:  J Neurol       Date:  1989-10       Impact factor: 4.849

3.  EEG sleep patterns in Parkinsonian patients treated with bromocryptine and L-dopa: a comparative study.

Authors:  J Vardi; H Glaubman; J Rabey; M Streifler
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

4.  Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study.

Authors:  Fabio Placidi; Francesca Izzi; Andrea Romigi; Paolo Stanzione; Maria Grazia Marciani; Livia Brusa; Francesca Sperli; Salvatore Galati; Patrizio Pasqualetti; Mariangela Pierantozzi
Journal:  J Neurol       Date:  2008-06-02       Impact factor: 4.849

5.  Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea.

Authors:  Ariel B Neikrug; Lianqi Liu; Julie A Avanzino; Jeanne E Maglione; Loki Natarajan; Lenette Bradley; Alex Maugeri; Jody Corey-Bloom; Barton W Palmer; Jose S Loredo; Sonia Ancoli-Israel
Journal:  Sleep       Date:  2014-01-01       Impact factor: 5.849

6.  Myoclonic attacks induced by L-dopa and bromocryptin in Parkinson patients: a sleep EEG study.

Authors:  J Vardi; H Glaubman; J M Rabey; M Streifler
Journal:  J Neurol       Date:  1978-04-14       Impact factor: 4.849

7.  Serial macro-architectural alterations with levodopa in Parkinson's disease: Polysomnography (PSG)-based analysis.

Authors:  Sanju P Joy; Sanjib Sinha; Pramod Kumar Pal; Samhita Panda; M Philip; Arun B Taly
Journal:  Ann Indian Acad Neurol       Date:  2015 Jul-Sep       Impact factor: 1.383

8.  Cognitive Impairments and Self-Reported Sleep in Early-Stage Parkinson's Disease with Versus without Probable REM Sleep Behavior Disorder.

Authors:  Jonathan Trout; Taylor Christiansen; M Brooks Bulkley; Jared J Tanner; Christopher N Sozda; Dawn Bowers; Daniel B Kay
Journal:  Brain Sci       Date:  2019-12-21

Review 9.  Physiological and anatomical link between Parkinson-like disease and REM sleep behavior disorder.

Authors:  Yuan-Yang Lai; Jerome M Siegel
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

10.  Sleep disturbances and depression severity in patients with Parkinson's disease.

Authors:  Daniel B Kay; Jared J Tanner; Dawn Bowers
Journal:  Brain Behav       Date:  2018-04-23       Impact factor: 2.708

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.